445 related articles for article (PubMed ID: 29321164)
21. Loss of the wild-type KRAS allele promotes pancreatic cancer progression through functional activation of YAP1.
Yan H; Yu CC; Fine SA; Youssof AL; Yang YR; Yan J; Karg DC; Cheung EC; Friedman RA; Ying H; Chen EI; Luo J; Miao Y; Qiu W; Su GH
Oncogene; 2021 Dec; 40(50):6759-6771. PubMed ID: 34663879
[TBL] [Abstract][Full Text] [Related]
22. Critical role of oncogenic KRAS in pancreatic cancer (Review).
Liu J; Ji S; Liang C; Qin Y; Jin K; Liang D; Xu W; Shi S; Zhang B; Liu L; Liu C; Xu J; Ni Q; Yu X
Mol Med Rep; 2016 Jun; 13(6):4943-9. PubMed ID: 27121414
[TBL] [Abstract][Full Text] [Related]
23. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
Zhao X; Wang X; Fang L; Lan C; Zheng X; Wang Y; Zhang Y; Han X; Liu S; Cheng K; Zhao Y; Shi J; Guo J; Hao J; Ren H; Nie G
Cancer Lett; 2017 Aug; 402():61-70. PubMed ID: 28576749
[TBL] [Abstract][Full Text] [Related]
24. A FAM83A Positive Feed-back Loop Drives Survival and Tumorigenicity of Pancreatic Ductal Adenocarcinomas.
Parameswaran N; Bartel CA; Hernandez-Sanchez W; Miskimen KL; Smigiel JM; Khalil AM; Jackson MW
Sci Rep; 2019 Sep; 9(1):13396. PubMed ID: 31527715
[TBL] [Abstract][Full Text] [Related]
25. Eukaryotic Translation Initiation Factor 5A (EIF5A) Regulates Pancreatic Cancer Metastasis by Modulating RhoA and Rho-associated Kinase (ROCK) Protein Expression Levels.
Fujimura K; Choi S; Wyse M; Strnadel J; Wright T; Klemke R
J Biol Chem; 2015 Dec; 290(50):29907-19. PubMed ID: 26483550
[TBL] [Abstract][Full Text] [Related]
26. PEAK1, acting as a tumor promoter in colorectal cancer, is regulated by the EGFR/KRas signaling axis and miR-181d.
Huang L; Wen C; Yang X; Lou Q; Wang X; Che J; Chen J; Yang Z; Wu X; Huang M; Lan P; Wang L; Iwamoto A; Wang J; Liu H
Cell Death Dis; 2018 Feb; 9(3):271. PubMed ID: 29449544
[TBL] [Abstract][Full Text] [Related]
27. Blockade of EIF5A hypusination limits colorectal cancer growth by inhibiting MYC elongation.
Coni S; Serrao SM; Yurtsever ZN; Di Magno L; Bordone R; Bertani C; Licursi V; Ianniello Z; Infante P; Moretti M; Petroni M; Guerrieri F; Fatica A; Macone A; De Smaele E; Di Marcotullio L; Giannini G; Maroder M; Agostinelli E; Canettieri G
Cell Death Dis; 2020 Dec; 11(12):1045. PubMed ID: 33303756
[TBL] [Abstract][Full Text] [Related]
28. Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis.
Santana-Codina N; Roeth AA; Zhang Y; Yang A; Mashadova O; Asara JM; Wang X; Bronson RT; Lyssiotis CA; Ying H; Kimmelman AC
Nat Commun; 2018 Nov; 9(1):4945. PubMed ID: 30470748
[TBL] [Abstract][Full Text] [Related]
29. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma.
Ju HQ; Ying H; Tian T; Ling J; Fu J; Lu Y; Wu M; Yang L; Achreja A; Chen G; Zhuang Z; Wang H; Nagrath D; Yao J; Hung MC; DePinho RA; Huang P; Xu RH; Chiao PJ
Nat Commun; 2017 Feb; 8():14437. PubMed ID: 28232723
[TBL] [Abstract][Full Text] [Related]
30. NFATc1 Links EGFR Signaling to Induction of Sox9 Transcription and Acinar-Ductal Transdifferentiation in the Pancreas.
Chen NM; Singh G; Koenig A; Liou GY; Storz P; Zhang JS; Regul L; Nagarajan S; Kühnemuth B; Johnsen SA; Hebrok M; Siveke J; Billadeau DD; Ellenrieder V; Hessmann E
Gastroenterology; 2015 May; 148(5):1024-1034.e9. PubMed ID: 25623042
[TBL] [Abstract][Full Text] [Related]
31. IKBKE Is Required during KRAS-Induced Pancreatic Tumorigenesis.
Rajurkar M; Dang K; Fernandez-Barrena MG; Liu X; Fernandez-Zapico ME; Lewis BC; Mao J
Cancer Res; 2017 Jan; 77(2):320-329. PubMed ID: 28069799
[TBL] [Abstract][Full Text] [Related]
32. Regulation of oncogenic KRAS signaling via a novel KRAS-integrin-linked kinase-hnRNPA1 regulatory loop in human pancreatic cancer cells.
Chu PC; Yang MC; Kulp SK; Salunke SB; Himmel LE; Fang CS; Jadhav AM; Shan YS; Lee CT; Lai MD; Shirley LA; Bekaii-Saab T; Chen CS
Oncogene; 2016 Jul; 35(30):3897-908. PubMed ID: 26616862
[TBL] [Abstract][Full Text] [Related]
33. Loss of the transcriptional repressor TGIF1 results in enhanced Kras-driven development of pancreatic cancer.
Weng CC; Hsieh MJ; Wu CC; Lin YC; Shan YS; Hung WC; Chen LT; Cheng KH
Mol Cancer; 2019 May; 18(1):96. PubMed ID: 31109321
[TBL] [Abstract][Full Text] [Related]
34. Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer.
Yao W; Rose JL; Wang W; Seth S; Jiang H; Taguchi A; Liu J; Yan L; Kapoor A; Hou P; Chen Z; Wang Q; Nezi L; Xu Z; Yao J; Hu B; Pettazzoni PF; Ho IL; Feng N; Ramamoorthy V; Jiang S; Deng P; Ma GJ; Den P; Tan Z; Zhang SX; Wang H; Wang YA; Deem AK; Fleming JB; Carugo A; Heffernan TP; Maitra A; Viale A; Ying H; Hanash S; DePinho RA; Draetta GF
Nature; 2019 Apr; 568(7752):410-414. PubMed ID: 30918400
[TBL] [Abstract][Full Text] [Related]
35. The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer.
Diehl JN; Klomp JE; Snare KR; Hibshman PS; Blake DR; Kaiser ZD; Gilbert TSK; Baldelli E; Pierobon M; Papke B; Yang R; Hodge RG; Rashid NU; Petricoin EF; Herring LE; Graves LM; Cox AD; Der CJ
J Biol Chem; 2021 Nov; 297(5):101335. PubMed ID: 34688654
[TBL] [Abstract][Full Text] [Related]
36. RAGE maintains high levels of NFκB and oncogenic Kras activity in pancreatic cancer.
Azizan N; Suter MA; Liu Y; Logsdon CD
Biochem Biophys Res Commun; 2017 Nov; 493(1):592-597. PubMed ID: 28867179
[TBL] [Abstract][Full Text] [Related]
37. TGIF1 functions as a tumor suppressor in pancreatic ductal adenocarcinoma.
Parajuli P; Singh P; Wang Z; Li L; Eragamreddi S; Ozkan S; Ferrigno O; Prunier C; Razzaque MS; Xu K; Atfi A
EMBO J; 2019 Jul; 38(13):e101067. PubMed ID: 31268604
[TBL] [Abstract][Full Text] [Related]
38. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function.
Viale A; Pettazzoni P; Lyssiotis CA; Ying H; Sánchez N; Marchesini M; Carugo A; Green T; Seth S; Giuliani V; Kost-Alimova M; Muller F; Colla S; Nezi L; Genovese G; Deem AK; Kapoor A; Yao W; Brunetto E; Kang Y; Yuan M; Asara JM; Wang YA; Heffernan TP; Kimmelman AC; Wang H; Fleming JB; Cantley LC; DePinho RA; Draetta GF
Nature; 2014 Oct; 514(7524):628-32. PubMed ID: 25119024
[TBL] [Abstract][Full Text] [Related]
39. Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo.
Qiu W; Sahin F; Iacobuzio-Donahue CA; Garcia-Carracedo D; Wang WM; Kuo CY; Chen D; Arking DE; Lowy AM; Hruban RH; Remotti HE; Su GH
Oncotarget; 2011 Nov; 2(11):862-73. PubMed ID: 22113502
[TBL] [Abstract][Full Text] [Related]
40. Oncogenic signaling pathways in pancreatic ductal adenocarcinoma.
Agrawal R; Natarajan KN
Adv Cancer Res; 2023; 159():251-283. PubMed ID: 37268398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
